Tenofovir, a key drug used in the study, has since been dropped after it failed to shield participants from contracting the virus.
Vaginal and Oral Interventions to Control the Epidemic (VOICE) project director Dr Nyaradzo Mgodi told The Sunday Mail last Friday that the women were part of a group that was always at risk of infection.
She said the project co-ordinators were still working to establish the exact number of the infected. She said participants who tested positive will receive HIV counselling, contraceptives and other medical support services. The participants are predominantly sexually active married or single women who live in communities with a high HIV prevalence
“The decision to discontinue the use of the Tenofovir tablet in VOICE came after the drugs were found to be ineffective in preventing HIV contraction among the women enrolled for the trials,”